Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer

Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity

(2015) Shuya Yano et al.   Oncotarget

Tumor-targetingSalmonella typhimuriumA1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy

(2014) Shuya Yano et al.   CELL CYCLE

Spatial–temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness

(2014) Shuya Yano et al.   CELL CYCLE

Nab-paclitaxel: A flattering facelift

(2014) A. Viúdez et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer

(2014) Sheridan M. Hoy   DRUGS

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

(2013) R Alvarez et al.   BRITISH JOURNAL OF CANCER

A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem-like Cells in S/G2/M Phases

(2013) S. Yano et al.   CLINICAL CANCER RESEARCH

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

(2012) Paolo P. Provenzano et al.   CANCER CELL

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular effects of systemic cancer treatment

(2010) Elżbieta Senkus et al.   CANCER TREATMENT REVIEWS